Bone Mineral Density

Osteoporosis

Phase 3 Trial Results for Investigational Sclerostin Inhibitor

Corinna Sison, MD

March 28, 2016

Amgen and UCB announced results from a phase 3 study evaluating romosozumab for the treatment of osteoporosis in men.

Osteoporosis

Changes in Bisphosphonate Use Resulting From FDA Safety Anouncements

March 16, 2016

The usage of bisphosphonates decreased as a result of safety announcements issued by the United States Food and Drug Administration (FDA) regarding potential adverse effects of bisphosphonates after hip fracture.

Osteoporosis

Updated Recommendations for Development of Peak Bone Mass

Corinna Sison, MD

February 23, 2016

Following a systematic evidence review, the National Osteoporosis Foundation (NOF) has developed practice guidelines based on the graded strength of current evidence.